Keys to Success in Clinical Trials: A Strategic Guide for Biotechs and Startups
Register for this webinar today to help biotechs navigate endpoint challenges in clinical trials and accelerate their path to drug approval.
Session information:
Time:
- 11:00 a.m. – 12:00 p.m. ET (NA-East)
- 16:00 – 17:00 BST (UK)
- 17:00 – 18:00 CET (EU-Central)
Abstract:
For biotechnology companies and startups, selecting the right clinical trial endpoints is essential for regulatory success, investor confidence and efficient trial execution.
This webinar will explore best practices for endpoint strategy, ensuring alignment with scientific and regulatory expectations while balancing feasibility and cost. The expert panel will discuss key considerations for endpoint selection, the role of operational excellence in trial execution and strategies for mitigating risks through project assurance.
Attendees will gain insights into optimizing trial design, selecting the right CRO partners and leveraging innovative technologies to generate high-quality, reliable clinical evidence. Through real-world case studies and proven methodologies, this session will equip biotechs with the information needed to enhance trial efficiency, minimize delays and accelerate their path to approval.
Speakers
Todd Rudo, M.D.
EVP & Chief Medical Officer at Clario
Dr. Todd Rudo is EVP and Chief Medical Officer at Clario, providing medical and scientific leadership across the organization. He has nearly 20 years of clinical cardiology and pharmaceutical research experience, with a career predominantly focused on drug safety. Dr. Rudo has board certifications in cardiology, cardiac electrophysiology, nuclear cardiology, adult echocardiography and internal medicine. His team provides expert consulting to clients on scientific and regulatory strategy, and ensures Clario’s product portfolio is scientifically robust, generating high quality clinical trial endpoint data. Dr. Rudo has a particular interest in applying innovative technologies to improve the scientific rigor of clinical trials, while maintaining focus on the customer experience, including minimizing patient and site burden.
Chris Clendening
SVP, Biotechnology Operations at Clario
Chris Clendening is SVP of Biotechnology Operations at Clario, focused on providing and developing enhanced delivery models for our Biotech clients across the organization. He has 20 years of experience working across pharmaceutical research, development and clinical trials. Chris has extensive knowledge managing the complexities of clinical trials while in the central lab industry and applying innovative solutions for pharmaceutical clients. He is focused on building a comprehensive model focused on speed, efficiency and exceptional delivery to enhance Clario’s overall offering to our Biotech clients. His history of bringing these tools and tailor-made services to the market demonstrates Clario’s continued commitment to maintaining their best-in-class offering. Chris’ interest lies in bending the time/cost curve across the entire clinical trial continuum while providing enhanced proactive data analytics with the highest integrity.
John Ohrn
SVP, Global Sales and Customer Success at Clario
John has been working with Life Sciences Organizations across the research and development spectrum. For the past decade, he has focused on enabling contract research organizations (CROs) and Sponsors to develop execution models for delivering Clinical Research to patients and sites. Currently serving as Senior Vice President of Global Sales and Customer Success at Clario, John has played a pivotal role in continuing Clario’s leadership position in multiple therapeutic areas and research modalities. Prior to Clario, John held senior leadership positions at Medable, Medidata Solutions, and Microsoft, consistently delivering growth, expanding market presence, and strengthening strategic alliances with top biopharmaceutical and CRO partners. John blends industry expertise with a deep understanding of the life sciences ecosystem. A passionate advocate for leveraging technology to transform clinical research, John takes a pragmatic approach to trial execution, strategy, and operational excellence and is an early advocate for AI-driven clinical trial solutions.